ANIKA THERAPEUTICS INC (ANIK) Stock Fundamental Analysis
USA - NASDAQ:ANIK - US0352551081 - Common Stock
9.99 USD
-0.11 (-1.09%)
9.99 USD
0 (0%)
Overall ANIK gets a fundamental rating of 4 out of 10. We evaluated ANIK against 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANIK as it has an excellent financial health rating, but there are worries on the profitability. ANIK is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ANIK has reported negative net income.
ANIK had a positive operating cash flow in the past year.
ANIK had negative earnings in 4 of the past 5 years.
ANIK had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -32.30%, ANIK is doing good in the industry, outperforming 64.60% of the companies in the same industry.
ANIK has a better Return On Equity (-41.05%) than 70.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.3% | ||
| ROE | -41.05% | ||
| ROIC | N/A |
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ANIK (56.82%) is better than 77.40% of its industry peers.
In the last couple of years the Gross Margin of ANIK has declined.
The Profit Margin and Operating Margin are not available for ANIK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
2. Health
2.1 Basic Checks
ANIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ANIK has been reduced compared to 1 year ago.
ANIK has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 3.63 indicates that ANIK is not in any danger for bankruptcy at the moment.
The Altman-Z score of ANIK (3.63) is better than 72.50% of its industry peers.
ANIK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.63 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
ANIK has a Current Ratio of 6.18. This indicates that ANIK is financially healthy and has no problem in meeting its short term obligations.
ANIK has a Current ratio of 6.18. This is in the better half of the industry: ANIK outperforms 65.54% of its industry peers.
ANIK has a Quick Ratio of 5.12. This indicates that ANIK is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 5.12, ANIK perfoms like the industry average, outperforming 57.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.18 | ||
| Quick Ratio | 5.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 53.18% over the past year.
ANIK shows a decrease in Revenue. In the last year, the revenue decreased by -0.73%.
ANIK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.91% yearly.
EPS 1Y (TTM)53.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)-0.73%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-28.22%
3.2 Future
ANIK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.24% yearly.
Based on estimates for the next years, ANIK will show a quite strong growth in Revenue. The Revenue will grow by 11.88% on average per year.
EPS Next Y36.93%
EPS Next 2Y23.87%
EPS Next 3Y22.04%
EPS Next 5Y28.24%
Revenue Next Year-25.9%
Revenue Next 2Y-11.97%
Revenue Next 3Y-6.61%
Revenue Next 5Y11.88%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ANIK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANIK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ANIK's earnings are expected to grow with 22.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.87%
EPS Next 3Y22.04%
5. Dividend
5.1 Amount
No dividends for ANIK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.99
-0.11 (-1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners88.97%
Inst Owner Change-4.05%
Ins Owners4.2%
Ins Owner Change17.04%
Market Cap144.06M
Revenue(TTM)119.91M
Net Income(TTM)-60.63M
Analysts85
Price Target15.81 (58.26%)
Short Float %2.25%
Short Ratio2.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-70.46%
Min EPS beat(2)-132.56%
Max EPS beat(2)-8.36%
EPS beat(4)0
Avg EPS beat(4)-518.35%
Min EPS beat(4)-1533.99%
Max EPS beat(4)-8.36%
EPS beat(8)0
Avg EPS beat(8)-472.04%
EPS beat(12)2
Avg EPS beat(12)-316.38%
EPS beat(16)5
Avg EPS beat(16)-229.59%
Revenue beat(2)1
Avg Revenue beat(2)-3.13%
Min Revenue beat(2)-8.59%
Max Revenue beat(2)2.34%
Revenue beat(4)2
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-9.72%
Max Revenue beat(4)3.46%
Revenue beat(8)5
Avg Revenue beat(8)-0.68%
Revenue beat(12)8
Avg Revenue beat(12)0.79%
Revenue beat(16)12
Avg Revenue beat(16)2.36%
PT rev (1m)0%
PT rev (3m)-15.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.22%
EPS NY rev (1m)-8.94%
EPS NY rev (3m)-16.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.16 | ||
| P/FCF | N/A | ||
| P/OCF | 22.94 | ||
| P/B | 0.98 | ||
| P/tB | 1.04 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.28
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)0.44
OCFY4.36%
SpS8.58
BVpS10.24
TBVpS9.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.3% | ||
| ROE | -41.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.82% | ||
| FCFM | N/A |
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
F-Score6
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 105.79% | ||
| Cap/Sales | 5.99% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.18 | ||
| Quick Ratio | 5.12 | ||
| Altman-Z | 3.63 |
F-Score6
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)64.17%
Cap/Depr(5y)48.11%
Cap/Sales(3y)5.41%
Cap/Sales(5y)4.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y36.93%
EPS Next 2Y23.87%
EPS Next 3Y22.04%
EPS Next 5Y28.24%
Revenue 1Y (TTM)-0.73%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-28.22%
Revenue Next Year-25.9%
Revenue Next 2Y-11.97%
Revenue Next 3Y-6.61%
Revenue Next 5Y11.88%
EBIT growth 1Y9.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year105.4%
EBIT Next 3Y32.7%
EBIT Next 5Y36.1%
FCF growth 1Y92.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y172.01%
OCF growth 3Y-13.68%
OCF growth 5Y-31.94%
ANIKA THERAPEUTICS INC / ANIK FAQ
What is the fundamental rating for ANIK stock?
ChartMill assigns a fundamental rating of 4 / 10 to ANIK.
Can you provide the valuation status for ANIKA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 1 / 10 to ANIKA THERAPEUTICS INC (ANIK). This can be considered as Overvalued.
Can you provide the profitability details for ANIKA THERAPEUTICS INC?
ANIKA THERAPEUTICS INC (ANIK) has a profitability rating of 2 / 10.
How financially healthy is ANIKA THERAPEUTICS INC?
The financial health rating of ANIKA THERAPEUTICS INC (ANIK) is 8 / 10.
What is the expected EPS growth for ANIKA THERAPEUTICS INC (ANIK) stock?
The Earnings per Share (EPS) of ANIKA THERAPEUTICS INC (ANIK) is expected to grow by 36.93% in the next year.